Karuna Therapeutics’ late-stage drug for schizophrenia, if approved, could fund the company’s pipeline of next generation psychiatric drugs discovered through a modular constellation of CRO partners.

Ninety-four percent of PhRMA’s member companies responding to a survey published in December 2020 reported the existence of “employee resource groups” within their organizations, defined as an “employer recognized group of employees who share the concerns of a common race, gender, national origin, or sexual orientation.”

Can Bayer’s “arm’s-length model” for acquired companies help turn the century-and-a-half year-old Big Pharma into a leader in gene and cell therapy, and a top 10 player in oncology?

Alnylam CEO Yvonne Greenstreet talks about what’s next for the company, including a transition into larger therapeutic areas and patient populations, and describes her own journey to the CEO role.  

Representation at the top of any profession, whether jurisprudence or biotechnology, works as an accelerator for younger generations to follow.

KemPharm’s experience in reworking product NDAs following FDA Complete Response Letters has created a unique capability within the company, and helped it move to acquire a potentially valuable asset from distressed biopharma Orphazyme.

When CEO Avanish Vellanki founded and incorporated Rain Therapeutics on his living room couch in the spring of 2017, there was no drug in development, no money, and a team of only four people.

Albireo Pharma CEO Ron Cooper discusses the company’s three approaches to commercializing orphan drugs globally, and how to go from topline data to regulatory filing in 70 days. 

With bad news in the headlines at home and globally, and a seesawing public market capable of wiping years of value from company books almost overnight, it can be difficult to remain focused on the bread-and-butter tasks that keep a company afloat.